UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 11, 2016
PRESSURE
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Massachusetts |
|
000-21615 |
|
04-2652826 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
14
Norfolk Avenue
South
Easton, Massachusetts 02375
(Address
of principal executive offices)(Zip Code)
Registrant’s
telephone number, including area code: (508) 230-1828
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Cautionary
Note on Forward-Looking Statements
This
Current Report on Form 8-K (this “Report”) contains, or may contain, among other things, certain “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”),
and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking
statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect
to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such
as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,”
or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management
and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities
and Exchange Commission (the “SEC”). Actual results may differ significantly from those set forth in the forward-looking
statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various
factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Item
1.01 Entry into a Material Definitive Agreement.
On
January 11, 2016, in connection with the fifth closing (the “Fifth Closing”) of a private placement equity
financing previously disclosed by Pressure BioSciences Inc. (the “Company”) on its Current Report on Form 8-K
filed by the Company on July 28, 2015 (the “July 28 Current Report”), which is incorporated by reference herein
(excluding Exhibit 99.1 thereto), and pursuant to the Subscription Agreements, dated as of December 18, 2015, December 31, 2015
and January 8, 2016 by and among the Company and various individuals (each, a “Purchaser” and together “Purchasers”)
the Company sold and issued to the Purchasers Senior Secured Convertible Debentures (the “Debentures”) and
warrants to purchase shares of common stock equal to 50% of the number of shares issuable pursuant to the subscription amount
(the “Warrants”) for an aggregate purchase price of $255,000 (the “Purchase Price”) for
the Fifth Closing, bringing the total raised in the Offering to $5,010,000. For the Fifth Closing, the Company netted $229,500
in cash after taking into account fees related to the Offering.
As
disclosed in the July 28 Current Report, the total amount of the private placement equity financing could be up to $5,000,000
with an over-subscription amount of $1,250,000. Since this $5,000,000 limit was approaching, the Company approved the over-subscription
amount of $1,250,000, increasing the capacity of the private placement equity financing to a maximum of $6,250,000.
In
connection with the Subscription Agreement and Debentures, the Company entered into a Security Agreement with the Purchasers and
a FINRA-registered broker dealer that acted as the placement agent whereby the Company agreed to grant to Purchasers an unconditional
and continuing, first priority security interest in all of the assets and property of the Company to secure the prompt payment,
performance and discharge in full of all of Company’s obligations under the Debentures, Warrants and the other transaction
documents. The form of Subscription Agreement, form of Debenture, form of Warrant, and Security Agreement were filed as Exhibit
10.1, 4.1, 4.2, and 10.2 to the July 28 Current Report respectively, each of which is incorporated by reference herein.
Item
3.02 Unregistered Sales of Equity Securities.
Reference
is made to the disclosure set forth under Item 1.01 of this Report, which disclosure is incorporated herein by reference.
The
issuance of the securities described above were completed in accordance with the exemption provided by Section 4(a)(2) of the
Securities Act of 1933, as amended.
Item
8.01 Other Items
On
January 11, 2016, we issued a press release relating to this Fifth Closing. The press release is attached hereto as Exhibit 99.1.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
Exhibit
Number
|
|
Exhibit
Description |
|
|
|
4.1 |
|
Form
of Debenture (incorporated by reference to the Current Report on Form 8-K, dated July 28, 2015) |
|
|
|
4.2 |
|
Form
of Warrant (incorporated by reference to the Current Report on Form 8-K, dated July 28, 2015) |
|
|
|
10.1 |
|
Subscription
Agreement (incorporated by reference to the Current Report on Form 8-K, dated July 28, 2015) |
|
|
|
10.2 |
|
Security
Agreement (incorporated by reference to the Current Report on Form 8-K, dated July 28, 2015) |
|
|
|
99.1 |
|
Press
Release |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
PRESSURE
BIOSCIENCES, INC. |
|
|
|
Dated:
January 15, 2016 |
By: |
/s/
Richard T. Schumacher |
|
|
Richard
T. Schumacher |
|
|
President |
FOR
IMMEDIATE RELEASE
Investor
Contacts: |
|
Richard
T. Schumacher, President & CEO, PBI |
(508)
230-1828 (T) |
Jeffrey
N. Peterson, Chairman, PBI |
(650)
812-8121 (T) |
Redwood
Investment Group |
(714)
978-4425 (T) |
Pressure
BioSciences Exceeds $5 Million PIPE Goal
and
Opens $1.25 Million Over-Subscription Amount
South
Easton, MA, January 11, 2016 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”),
a leader in the development and sale of broadly enabling, pressure cycling technology (“PCT”)-based sample preparation
solutions to the worldwide life sciences industry, today announced it has exceeded its $5 million PIPE goal following the receipt
of $255,000 in gross proceeds from the fifth closing of its $5 million Private Placement (the “Offering”). This closing
increased the total amount raised in the Offering to $5,010,000.
Since
the terms of the Offering limit the amount that can be raised to $5 million, the Company has approved the opening of the $1.25
million over-subscription amount, which has increased the capacity of the PIPE to a maximum of $6.25 million.
Pursuant
to the Subscription Agreement, the Company will issue to the investors, senior secured convertible debentures with a fixed conversion
price of $0.28 per restricted common share, and common stock purchase warrants exercisable into a total of 455,357 shares of restricted
common stock at an exercise price of $0.40 per share. The Company is under no obligation to file a registration statement to register
the shares underlying the Debentures and Warrants.
Mr.
Richard T. Schumacher, President and CEO of PBI, commented: “The vast majority of funds raised to date have been used to
eliminate 100% of the Company’s variable rate (floorless) convertible debt. With our significantly improved balance sheet
now in hand, all funds received from the over-subscription amount will be used to support operating activities. With ramping sales,
new and further improved product offerings, the planned expansion of our sales and marketing capabilities, and the expected announcement
of a world-class, formidable, multi-national co-marketing partner, we believe we will achieve operational and financial growth
levels in 2016 that will surpass any previous year, including our record shattering 2015 performance.”
This
press release is not an offer to sell or a solicitation of offers to participate in the Offering. The units, including the shares
underlying the Debentures and Warrants, have not been registered under the Securities Act and may not be sold in the United States
absent registration under the Securities Act or an applicable exemption from registration.
For
more information on the Offering, please see the Form 8-K filed by the Company on July 28, 2015.
About
Pressure BioSciences, Inc.
Pressure
BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated
consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties
of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely
and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites
worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion
leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also
use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology,
vaccine development, histology, and forensic applications.
Forward
Looking Statements
Statements
contained in this press release regarding PBI’s intentions, hopes, beliefs, expectations, or predictions of the future are
“forward-looking’’ statements within the meaning of the Private Securities Litigation Reform Act of 1995. These
statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties,
and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking
statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed
under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31,
2014, in the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2015, and other reports filed by
the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in
this release, except as otherwise required by law.
For
more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please
visit us on Facebook, LinkedIn, and Twitter
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024